{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:31:07Z","timestamp":1787225467051,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Bayerisches Zentrum f\u00fcr Krebsforschung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"DOI":"10.1007\/s00066-026-02584-3","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:16:07Z","timestamp":1787224567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter ProKnow-based plan evaluation of postprostatectomy salvage radiotherapy patients using SPPORT and RADICALS-HD trial-defined dose constraints"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9885-9893","authenticated-orcid":false,"given":"Michael","family":"Keilholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F.","family":"Moar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian H.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Z\u00e4hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Sch\u00f6necker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Putz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"S\u00fc\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Treutwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Angnostatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2584_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.ju.0000045749.90353.c7","volume":"169","author":"M Han","year":"2003","unstructured":"Han\u00a0M, Partin\u00a0AW, Zahurak\u00a0M, Piantadosi\u00a0S, Epstein\u00a0JI, Walsh\u00a0PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J\u00a0Urol 169:517\u2013523. https:\/\/doi.org\/10.1097\/01.ju.0000045749.90353.c7","journal-title":"J Urol"},{"key":"2584_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urolonc.2006.06.003","volume":"25","author":"GP Swanson","year":"2007","unstructured":"Swanson\u00a0GP, Riggs\u00a0M, Hermans\u00a0M (2007) Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 25:110\u2013114. https:\/\/doi.org\/10.1016\/j.urolonc.2006.06.003","journal-title":"Urol Oncol"},{"key":"2584_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70988","volume":"14","author":"SP Basourakos","year":"2025","unstructured":"Basourakos\u00a0SP, Boorjian\u00a0SA, Schulte\u00a0PJ et\u00a0al (2025) Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Cancer Med 14:e70988. https:\/\/doi.org\/10.1002\/cam4.70988","journal-title":"Cancer Med"},{"key":"2584_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030740","author":"D Tilki","year":"2022","unstructured":"Tilki\u00a0D, Preisser\u00a0F, Thamm\u00a0R et\u00a0al (2022) Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers14030740","journal-title":"Cancers (Basel)"},{"key":"2584_CR5","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.22.02489","volume":"41","author":"D Tilki","year":"2023","unstructured":"Tilki\u00a0D, Chen\u00a0MH, Wu\u00a0J et\u00a0al (2023) Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J\u00a0Clin Oncol 41:2428\u20132435. https:\/\/doi.org\/10.1200\/JCO.22.02489","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2584_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley\u00a0WU, Seiferheld\u00a0W, Lukka\u00a0HR et\u00a0al (2017) Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 376:417\u2013428. https:\/\/doi.org\/10.1056\/NEJMoa1607529","journal-title":"N Engl J Med"},{"key":"2584_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","volume":"17","author":"C C","year":"2016","unstructured":"C\u00a0C, A\u00a0H, G de\u00a0L et\u00a0al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747\u2013756. https:\/\/doi.org\/10.1016\/S1470-2045(16)00111-X","journal-title":"Lancet Oncol"},{"key":"2584_CR8","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1007\/s00259-025-07255-6","volume":"52","author":"A Di Giorgio","year":"2025","unstructured":"Di Giorgio\u00a0A, Siepe\u00a0G, Serani\u00a0F et\u00a0al (2025) Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a\u00a05-year follow-up analysis. EJNMMI Rep 52:3720\u20133729. https:\/\/doi.org\/10.1007\/s00259-025-07255-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2584_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","volume":"80","author":"P Ghadjar","year":"2021","unstructured":"Ghadjar\u00a0P, Hayoz\u00a0S, Bernhard\u00a0J et\u00a0al (2021) Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09\/10 Randomized Phase 3 Trial. Eur Urol Oncol 80:306\u2013315. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.033","journal-title":"Eur Urol"},{"key":"2584_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/bju.15769","volume":"130","author":"K Braide","year":"2022","unstructured":"Braide\u00a0K, Kindblom\u00a0J, Thellenberg Karlsson\u00a0C, Stattin\u00a0P, Hugosson\u00a0J, M\u00e5nsson\u00a0M (2022) Risk of severe late toxicity after radiotherapy following radical prostatectomy - a\u00a0nationwide study. BJU Int 130:799\u2013808. https:\/\/doi.org\/10.1111\/bju.15769","journal-title":"BJU Int"},{"key":"2584_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111040","volume":"211","author":"C Schr\u00f6der","year":"2025","unstructured":"Schr\u00f6der\u00a0C, Zwahlen\u00a0DR, Sch\u00e4r\u00a0S et\u00a0al (2025) Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09\/10 dose escalation trial. Clin Transl Radiat Oncol 211:111040. https:\/\/doi.org\/10.1016\/j.radonc.2025.111040","journal-title":"Radiother Oncol"},{"key":"2584_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijrobp.2010.09.027","volume":"82","author":"C Cozzarini","year":"2012","unstructured":"Cozzarini\u00a0C, Fiorino\u00a0C, Da Pozzo\u00a0LF et\u00a0al (2012) Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a\u00a0single-institute analysis of 742 patients. Adv Radiat Oncol 82:191\u2013199. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2584_CR13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2011.08.006","volume":"60","author":"A Goenka","year":"2011","unstructured":"Goenka\u00a0A, Magsanoc\u00a0JM, Pei\u00a0X et\u00a0al (2011) Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol Oncol 60:1142\u20131148. https:\/\/doi.org\/10.1016\/j.eururo.2011.08.006","journal-title":"Eur Urol"},{"key":"2584_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/bjr\/tqae055","volume":"97","author":"S Takano","year":"2024","unstructured":"Takano\u00a0S, Tomita\u00a0N, Takaoka\u00a0T et\u00a0al (2024) Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses. Br J Radiol 97:1050\u20131056. https:\/\/doi.org\/10.1093\/bjr\/tqae055","journal-title":"Br J Radiol"},{"key":"2584_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctro.2018.05.001","volume":"11","author":"LF van Dessel","year":"2018","unstructured":"van Dessel\u00a0LF, Reuvers\u00a0SHM, Bangma\u00a0CH, Aluwini\u00a0S (2018) Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes. Clin Transl Radiat Oncol 11:26\u201332. https:\/\/doi.org\/10.1016\/j.ctro.2018.05.001","journal-title":"Clin Transl Radiat Oncol"},{"key":"2584_CR16","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker\u00a0CC, Kynaston\u00a0H, Cook\u00a0AD et\u00a0al (2024) Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet 403:2416\u20132425. https:\/\/doi.org\/10.1016\/S0140-6736(24)00549-X","journal-title":"Lancet"},{"key":"2584_CR17","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack\u00a0A, Karrison\u00a0TG, Balogh\u00a0AG et\u00a0al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399:1886\u20131901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6","journal-title":"Lancet"},{"key":"2584_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100790","volume":"47","author":"SH Maier","year":"2024","unstructured":"Maier\u00a0SH, Sch\u00f6necker\u00a0S, Anagnostatou\u00a0V et\u00a0al (2024) Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol 47:100790. https:\/\/doi.org\/10.1016\/j.ctro.2024.100790","journal-title":"Clin Transl Radiat Oncol"},{"key":"2584_CR19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200142","volume":"93","author":"T Taylor","year":"2020","unstructured":"Taylor\u00a0T, Richmond\u00a0N (2020) A\u00a0UK wide study of current prostate planning practice. Br J Radiol 93:20200142. https:\/\/doi.org\/10.1259\/bjr.20200142","journal-title":"Br J Radiol"},{"key":"2584_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2023.04.032","volume":"117","author":"PM Petersen","year":"2023","unstructured":"Petersen\u00a0PM, Cook\u00a0AD, Sydes\u00a0MR et\u00a0al (2023) Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial. Adv Radiat Oncol 117:624\u2013629. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.032","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02584-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:16:08Z","timestamp":1787224568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":20,"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02584-3","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Keilholz, E.F.\u00a0Moar, F.\u00a0Brose, S.H.\u00a0Maier, C.\u00a0Belka, P.\u00a0Rogowski, M.\u00a0Z\u00e4hringer, J.C.\u00a0Peeken, S.E.\u00a0Combs, S.\u00a0Sch\u00f6necker, F.\u00a0Putz, C.\u00a0S\u00fc\u00df, M.\u00a0Treutwein, V.\u00a0Angnostatou and N.\u00a0Schmidt-Hegemann declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is in accordance with the declaration of Helsinki and its subsequent amendments. The study protocol was approved by the institutional ethics committee (24-0686) and the need for written informed consent was waived.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}